7月9日，迈克生物今日收盘12.24元，上涨1.92%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到247.07倍，创65天以来新低，总市值74.97亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.36倍，行业中值37.22倍，迈克生物排 名第119位。 迈克生物股份有限公司的主营业务是体外诊断产品的研发、生产、销售和相关服务。公司的主要产品是 肝脏功能系列检测试剂、肾脏功能系列检测试剂、糖代谢系列检测试剂、脂代谢系列检测试剂、特殊蛋 白系列检测试剂、离子及其他系列检测试剂、心肌系列检测试剂、血栓与止血系列检测试剂、传染性疾 病系列检测试剂、生殖激素系列检测试剂、甲状腺功能系列检测试剂、肿瘤标志物系列检测试剂、唐氏 筛查系列检测试剂、优生优育系列检测试剂、骨代谢系列检测试剂、炎症系列检测试剂、贫血系列检测 试剂、自免类风湿系列检测试剂、自免ANA系列检测试剂、高血压系列检测试剂、过敏系列检测试 剂、核酸提取或纯化试剂、呼吸道系列检测试剂、肝炎系列检测试剂等。 最新一期业绩显示，2025年一季报，公司实现营业收入5.10亿元，同比-17.22%；净利润2397.96万元， 同 ...

7月3日，迈克生物今日收盘12.03元，上涨1.26%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到242.83倍，创19天以来新低，总市值73.68亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迈克生物242.8358.101.1673.68亿行业平均 51.4848.994.51106.54亿行业中值36.8836.802.4850.74亿1九安医疗10.2910.400.81173.59亿2英科医疗 10.4311.240.93164.74亿3新华医疗14.5213.461.1893.06亿4奥美医疗15.4115.101.5855.66亿5山东药玻 15.4515.501.78146.13亿6振德医疗15.5914.690.9956.59亿7康德莱15.8115.821.3134.07亿8维力医疗 16.5317.181.9437.69亿9九强生物16.5815.422.0382.13亿10奥泰生物16.6717.581.3553.17亿11安杰思 17.9218.142.1753.21亿12三鑫医疗18.8118.813.0942.78亿 来源：金融界 股东方面， ...

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.45倍，行业中值35.92倍，迈克生物排 名第118位。 来源：金融界 股东方面，截至2025年3月31日，迈克生物股东户数35022户，较上次减少1242户，户均持股市值35.28 万元，户均持股数量2.76万股。 6月26日，迈克生物今日收盘11.73元，下跌1.10%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到236.77倍，总市值71.84亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入5.10亿元，同比-17.22%；净利润2397.96万元， 同比-80.09%，销售毛利率56.76%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迈克生物236.7756.661.1371.84亿行业平均 49.4547.484.57105.42亿行业中值35.9237.582.3948.69亿1英科医疗9.6210.370.86152.00亿2九安医疗 10.1110.220.80170.60亿3新华医疗14.2313.191.1691.24亿4奥美医疗14.7414.451.5253.26亿5康德莱 15. ...

6月23日，迈克生物今日收盘11.65元，上涨1.57%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到235.16倍，总市值71.35亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均48.89倍，行业中值35.79倍，迈克生物排 名第118位。 最新一期业绩显示，2025年一季报，公司实现营业收入5.10亿元，同比-17.22%；净利润2397.96万元， 同比-80.09%，销售毛利率56.76%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迈克生物235.1656.271.1271.35亿行业平均 48.8947.044.50104.32亿行业中值35.7936.752.3948.75亿1英科医疗9.6210.370.86152.00亿2九安医疗 10.0410.150.79169.41亿3新华医疗14.1313.101.1590.58亿4康德莱14.8414.851.2331.97亿5奥美医疗 14.8814.581.5353.76亿6振德医疗15.2814.400.9755.48亿7山东药玻15.5515.601.79147.12亿8维力医疗 15.721 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)13迈克生物239.1957.241.1472.58亿行业平均 49.8047.814.58106.25亿行业中值36.8437.522.4050.04亿1英科医疗9.6610.420.86152.70亿2九安医疗 10.1710.290.80171.69亿3新华医疗14.4413.391.1892.58亿4振德医疗14.7513.900.9453.53亿5康德莱 15.0615.071.2532.45亿6山东药玻15.2015.241.75143.74亿7奥美医疗15.2514.941.5755.09亿8维力医疗 16.0516.691.8836.61亿9九强生物16.0614.931.9779.54亿10奥泰生物16.2017.081.3151.68亿11安杰思 17.5917.792.1352.21亿12三鑫医疗18.4618.473.0442.00亿 6月17日，迈克生物今日收盘11.85元，上涨1.54%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到239.19倍，总市值72.58亿元。 来源：金融界 迈克生物股份有限公司的主营业 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company, Maike Biological, within the medical device industry [1][2] - As of May 22, the company's stock closed at 11.7 yuan, down 1.68%, with a rolling PE ratio of 236.17 times and a total market capitalization of 7.166 billion yuan [1] - The average PE ratio for the medical device industry is 48.71 times, with a median of 35.37 times, placing Maike Biological at the 118th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, the company reported an operating revenue of 510 million yuan, a year-on-year decrease of 17.22%, and a net profit of 23.98 million yuan, down 80.09% year-on-year [2] - The company's sales gross margin stands at 56.76% [2] - The company specializes in the research, production, sales, and related services of in vitro diagnostic products, with a wide range of testing reagents for various medical conditions [1]

Group 1 - The core viewpoint of the news is that Maike Biological's stock performance and financial metrics indicate a significant decline in revenue and profit, alongside a high price-to-earnings (PE) ratio compared to industry averages [1][2][3] Group 2 - As of May 16, Maike Biological's stock closed at 12.07 yuan, with a PE ratio of 243.63, marking a new low in 28 days and a total market capitalization of 7.393 billion yuan [1] - The average PE ratio in the medical device industry is 49.40, with a median of 36.13, placing Maike Biological at the 117th position in the industry ranking [1][3] - For the first quarter of 2025, the company reported a revenue of 510 million yuan, a year-on-year decrease of 17.22%, and a net profit of 23.98 million yuan, down 80.09% year-on-year, with a gross margin of 56.76% [2]